Clinical updates review findings on risk of malignancy with pioglitazone, as well as various risk factors associated with insulin glargine use.
- Published in:
- 2012
- By:
- Publication type:
- Journal Article
Works matching IS 1082801X AND DT 2012 AND VI 47 AND IP 8
Results: 14
1
2
FDA user fee legislation speeds drug approvals, addresses shortages, counterfeits.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 306
- By:
- Publication type:
- Article
3
FDA warns of seizure risk for multiple sclerosis patients who take dalfampridine.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 305
- Publication type:
- Article
4
FDA actions in brief.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 281
- Publication type:
- Article
5
Delayed diagnosis, noncompliance, lack of communication, linked to hindering HIV care, IOM reports.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 277
- By:
- Publication type:
- Article
6
HCV screening projected to save 120,000 boomers' lives.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 275
- By:
- Publication type:
- Article
7
New oral anticoagulants for stroke prevention in atrial fibrillation: An update for managed care and hospital decision-makers.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 299
- By:
- Publication type:
- Article
8
Carfilzomib: A second-generation proteasome inhibitor for the treatment of multiple myeloma.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 282
- By:
- Publication type:
- Article
9
First-time generic approvals.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 281
- Publication type:
- Article
10
Few Americans attain CV health goals associated with decreased mortality.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 278
- Publication type:
- Article
11
New formulation.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 280
- Publication type:
- Article
12
New molecular entity.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 280
- Publication type:
- Article
13
Pipeline preview.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 280
- Publication type:
- Article
14
Cetuximab as an add-on to leucovorin, fluorouracil, and oxaliplatin for stage 3 colon cancer adds no benefit.
- Published in:
- Formulary, 2012, v. 47, n. 8, p. 278
- By:
- Publication type:
- Article